Interestingly, high Bcl3 expression was shown to correlate with reduced relapse-free survival (RFS) in breast cancer patients with tumours harbouring p53 mutations, suggesting that these patients may benefit most from Bcl3 targeting therapies. This evidence concerns the gene BCL3 and breast carcinoma.